257 related articles for article (PubMed ID: 17645829)
1. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Lin AM; Rini BI; Derynck MK; Weinberg V; Park M; Ryan CJ; Rosenberg JE; Bubley G; Small EJ
Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
[TBL] [Abstract][Full Text] [Related]
2. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
[TBL] [Abstract][Full Text] [Related]
6. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
[TBL] [Abstract][Full Text] [Related]
9. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Wilding G; Soulie P; Trump D; Das-Gupta A; Small E
Cancer; 2006 May; 106(9):1917-24. PubMed ID: 16568471
[TBL] [Abstract][Full Text] [Related]
10. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
Chittoor S; Berry W; Loesch D; Logie K; Fleagle J; Mull S; Boehm KA; Zhan F; Asmar L
Clin Genitourin Cancer; 2006 Dec; 5(3):212-8. PubMed ID: 17239275
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC
Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
18. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
19. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S
Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
